- Home
- MIST vs MFC Comparison
MIST vs MFC Comparison
Compare MIST & MFC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MIST | MFC |
|---|---|---|
| Founded | 2003 | 1887 |
| Country | Canada | Canada |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Life Insurance |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 146.9M | 72.1B |
| IPO Year | 2019 | 2002 |
Fundamental Metrics
Financial Performance| Metric | MIST | MFC |
|---|---|---|
| Price | $0.80 | $43.13 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 1 |
| Target Price | $8.00 | ★ $52.00 |
| AVG Volume (30 Days) | ★ 1.4M | 1.3M |
| Earning Date | 05-13-2026 | 05-13-2026 |
| Dividend Yield | N/A | ★ 3.40% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $2,915.14 | $40.66 |
| Revenue Next Year | N/A | $6.23 |
| P/E Ratio | ★ N/A | $16.52 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.75 | $30.92 |
| 52 Week High | $3.06 | $45.33 |
Technical Indicators
Market Signals| Indicator | MIST | MFC |
|---|---|---|
| Relative Strength Index (RSI) | 29.06 | 45.59 |
| Support Level | N/A | $41.80 |
| Resistance Level | $1.42 | $44.89 |
| Average True Range (ATR) | 0.06 | 0.64 |
| MACD | -0.01 | -0.07 |
| Stochastic Oscillator | 18.27 | 18.27 |
Price Performance
Historical ComparisonAbout MIST Milestone Pharmaceuticals Inc.
Milestone Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of cardiovascular medicines. Its approved product CARDAMYST (etripamil) nasal spray is available in the United States and is the self-administered treatment for use by patients anywhere, anytime an attack of PSVT occurs. It operates in single segment.
About MFC Manulife Financial Corporation
Manulife Financial is one of the Big Three Canadian life insurers. The firm provides life insurance, annuities, asset management, and wealth management products to individuals and group customers in Canada, the United States, and Asia. The Canadian business segment contributes approximately 21% of 2025 adjusted earnings. The Asia segment operates across 12 countries and contributes around 38% of earnings, with a significant presence in Hong Kong and Singapore. The US business, which primarily operates under the John Hancock brand, contributes about 16% of earnings. Manulife's global asset and wealth management business contributes approximately 25% of its earnings and had around CAD 1.1 trillion in assets under management and administration as of the end of 2025.